文献速递临床试验与 GCP

经鼻高流量氧疗与无创通气治疗钝性胸部创伤患者:随机对照试验方案

High-flow nasal cannula oxygen therapy versus noninvasive ventilation for patients with blunt chest trauma: protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2022-07-19

这是一项前瞻性、开放标签、多中心、非劣效性随机对照试验方案,纳入中度至重度钝性胸部创伤合并急性呼吸衰竭且无需立即插管的患者,在创伤后48小时内随机接受经鼻高流量氧疗或无创通气,主要结局为治疗失败,计划样本量562例,非劣效界值9%。

要点

  • 研究比较经鼻高流量氧疗与无创通气在中重度钝性胸部创伤合并急性呼吸衰竭患者中的治疗失败率。
  • 主要结局为治疗失败,定义为有创通气或呼吸支持模式转换(从经鼻高流量氧疗转为无创通气或反之)。
  • 基于α错误5%和β错误80%、非劣效界值9%,考虑潜在脱落和非参数分析,所需样本量为562例。

核心结论

  • 作者假设经鼻高流量氧疗在降低中重度钝性胸部创伤合并急性呼吸衰竭患者的治疗失败方面不劣于无创通气。
  • 研究结果应有助于判断经鼻高流量氧疗是否可作为无创通气的有效替代方案,尤其适用于不能耐受无创通气或有禁忌证的患者。

研究设计与样本

  • 前瞻性、开放标签、多中心、非劣效性随机对照试验。
  • 纳入中度至重度钝性胸部创伤合并急性呼吸衰竭(100mmHg < PaO2/FiO2 ≦ 200mmHg)且无需立即插管的患者,在创伤后48小时内随机分配至经鼻高流量氧疗组或无创通气组。
  • 基于α错误5%和β错误80%、非劣效界值9%,考虑潜在患者脱落和非参数分析,所需样本量为562例。

主要发现

  • 主要结局为治疗失败,定义为有创通气或呼吸支持模式转换(从经鼻高流量氧疗转为无创通气或反之)。
  • 次要结局包括开始经鼻高流量氧疗或无创通气治疗后2小时和12小时的动脉血气分析和生命体征,以及患者舒适度评分、呼吸困难评分、每日护理气道护理干预次数、肺炎或气胸发生率、面部皮肤破损、无创通气或经鼻高流量氧疗持续时间、28天死亡率以及ICU和住院总时长。

关键数值与推荐

  • 非劣效界值为9%。
  • 样本量562例基于α错误5%和β错误80%,考虑潜在脱落和非参数分析。
  • 纳入标准为中度至重度钝性胸部创伤合并急性呼吸衰竭,100mmHg < PaO2/FiO2 ≦ 200mmHg,且无需立即插管。
  • 随机化在创伤后48小时内进行。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-flow nasal cannula oxygen therapy (HFNC) is recommended by some scholars as an optimized respiratory support method for blunt chest trauma (BCT) patients. The basis of this recommendation is limited, however, and the efficacy of HFNC or noninvasive ventilation (NIV) in BCT patients has not yet been rigorously explored. This study aims to determine if HFNC is non-inferior to NIV in reducing treatment failure in moderate to severe BCT patients with acute respiratory failure. METHODS: This will be a prospective, open-label, multicenter, non-inferiority, randomized controlled trial. Moderate to severe BCT patients with acute respiratory failure (100mmHg < PaO2/FiO2 ≦ 200mmHg) who do not need immediate intubation will be randomized to HFNC or NIV within 48 h after trauma. The primary outcome is treatment failure, defined as invasive ventilation or a switch in respiratory support modality (from HFNC to NIV or vice-versa). Secondary outcomes include arterial blood gas analysis and vital signs at 2 and 12 h after initiating HFNC or NIV treatment, as well as patients' comfort scores, dyspnea scores, daily number of nursing airway care interventions, incidence of pneumonia or pneumothorax, facial skin breakdown, duration of NIV or HFNC, 28-day mortality, and total ICU and hospital lengths of stay. Based on an α error of 5% and a β error of 80%, with a non-inferiority limit of 9%, a sample size of 562 will be required to accomplish the trial goal, considering potential patient dropouts and nonparametric analysis. DISCUSSION: We hypothesize that HFNC will be non-inferior to NIV in reducing treatment failure in moderate to severe BCT with acute respiratory failure. The results should be useful for judging whether HFNC could be an effective alternative to NIV to treat moderate to severe BCT patients, especially for those who do not tolerate or have contraindications for NIV. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR1800017313 . Registered on July 24, 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zhu Q, Wang B, Li Y, et al. High-flow nasal cannula oxygen therapy versus noninvasive ventilation for patients with blunt chest trauma: protocol for a randomized controlled trial. Trials. 2022. PMID: 35854391. doi:10.1186/s13063-022-06507-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。